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ABSTRACT 
The understanding of cholesterol and its pathogenesis to Alzheimer’s disease (AD) pathogenic process is impor-
tant for the possible prevention of AD. High fibre diets that contain phytosterols have been shown to lower LDL 
and increase HDL cholesterol and are implicated in membrane cholesterol and amyloid beta (Aβ) homeostasis. 
The convergence of diet and AD may be related to the effects of phytosterols since plasma cholesterol is closely 
linked and regulated by phytosterols. Dietary fibre modifications that are low in fat and glucose reduce the risk 
for AD by not only effecting cell membranes and nutrient sensing G coupled receptors but also by regulating 
number of nuclear receptors such as histone deacetylases (HDAC) and peroxisome proliferator activated recep-
tors (PPAR) that control glucose, fatty acids and cholesterol and have significant effects on the brain cholesterol 
homeostasis and amyloidosis. The peripheral sink Aβ hypothesis indicates that the peripheral clearance of Aβ 
and its regulation by dietary phytosterols is of substantial interest since it may delay hypercholesterolemia and 
the early onset of amyloid plaque development. Liver disease has been of central importance with aging and 
programmed cell death pathways. Nutritional therapy has emerged as a novel approach to control appetite and 
the role of nutrigenomics as an early nutritional therapy may assist genes to delay liver and brain diseases such 
as Parkinson’s disease (PD) and Huntington’s disease (HD) that are associated with aging. The understanding of 
phytosterols and the role of these lipids in drug therapy such as cholesterol lowering drugs may provide molecu-
lar mechanisms that are involved in the regulation of cell Aβ clearance and metabolism. High fibre diets also 
contain various fatty acids such as the short chain fatty acids (SCFA) and the understanding of synergistic effects 
of SCFA and phytosterols in glucose regulation and cholesterol homeostasisis important to our understanding of 
diet, lifestyle and drugs in relation to peripheral amyloidosis and gene expression that play an early role in the 
development of AD. 
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1. Introduction 
Environmental factors such as exercise, circadian rhy- 
thms abnormalities, oxidative stress and aspects of vari-
ous diets in Western countries are now of considerable 
importance when considering the risk for Alzheimer’s 
disease (AD). The consumption of high fat and high cho- 
lesterol diets (HFHC) has clearly been associated with  
increased plasma cholesterol and oxidative stress in var- 
ious tissues. In various animal models of AD, a strong 
correlation has been found with HFHC diets and in- 
creased brain amyloid beta (Aβ) levels. The molecular 
mechanisms underlying the AD cholesterol connection 
are important in the prevention of the disease since con- 
siderable evidence indicates that cellular cholesterol le- 
vels, intracellular cholesterol transport and cholesterol 
esterification play an important role in Aβ generation and  *Corresponding author. 
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programmed cell death pathways. Specific diets and ex- 
tending lifespan with avoidance of programmed cell 
death pathways have become an urgent therapeutic in- 
tervention for anti-aging related diseases [1]. In Western 
countries, age related diseases such as obesity and di-
abetes have become common as risk factors for appetite 
dysregulation, atherosclerosis and AD [2]. The Western 
diet is known to be high in fat and cholesterol with ef- 
fects on the liver and brain lipid homeostasis and marked 
effects on peripheral amyloidosis [2]. 
The key element of this review is to improve the un- 
derstanding of cholesterol metabolism and its role in the 
prevention of AD. The role of therapeutic lipids such as 
phytosterols and fatty acids will be discussed that reduce 
hypercholesterolemia and improve the liver clearance of 
Aβ (peripheral sink Aβ hypothesis). The significance of 
nutritional therapy has emerged as a novel approach to 
control appetite and improve nutrigenomics that may 
activate genes involved in Aβ clearance and delay liver 
and brain diseases that are associated with aging. Mole- 
cular mechanisms that are involved in the regulation of 
cell Aβ clearance and metabolism require appropriate 
changes to diets such as high fibre diets that promote 
caloric restriction and allow consumption of diets that are 
low in fat and high in antioxidants, trace minerals and 
fish that are associated with appetite control and de-
creased risk for AD. The aim of these dietary strategies 
will accelerate liver and brain cholesterol metabolism 
with improvements and reversal of non alcoholic fatty 
liver disease (NAFLD) and maintenance of peripheral Aβ 
metabolism (Figure 1 ref [2]). 
Assessment of AD risk indicates that diet apart from 
genetic factors may provide a useful model for the pre- 
vention and management of the disease. Risk factors in- 
dicating that liver and metabolic health is central to AD 
have become important since memory loss and neurode- 
generative damage become essentially irreversible. There- 
fore, nutritional research has concentrated on the identi-
fication of nutrient sensing diets that provide regulation 
of histone deacetylases (HDAC) that are involved in ep-
igenetic control of gene expression that controls meta-
bolic and tissue glucose and cholesterol homeostasis 
[3,4]. In calorie restriction epigenetic regulation of genes 
that control lifespan [5,6], fatty acid acid [7] and aging is 
associated with an increase in the Sirtuin 1 (Sirt 1) pro- 
tein which is a member of the HDAC family [8]. HDAC 
and their dietary regulation are essential as therapy for 
glucose and cholesterol maintenance and reversal of neu- 
rodegeneration at early stages of AD [9-11]. 
Interests in cholesterol diets and sedentary lifestyles 
have become a major concern in Western countries and 
diets rich in fibre which may allow appropriate changes 
in calorie restriction and HDAC regulation with effects 
on liver cholesterol and glucose metabolism that main-  
 
Figure 1. Diets control appetite and cholesterol metabolism 
with the regulation of amyloid beta metabolism. 
 
tain active HDAC gene expression for peripheral Aβ me- 
tabolism and homeostasis [12,13]. Dietary fibre contains 
phytosterols, short chain fatty acids (SCFA) and other 
nutritional agents essential for reversing the effects of 
HFHC diets on down regulation of HDAC genes in- 
volved in cholesterol and Aβ homeostasis (Figure 1). 
Diets that are high in fat have been associated with 
hyperphagia and appetite associated hormones such as 
insulin, glucagon, ghrelin and leptin which have been 
found to be altered with these diets and exercise [14-18]. 
Interests in nutritional therapy by consumption of high 
fibre diets have important effects on appetite control [19- 
23] and activation liver nutrient receptors. NAFLD has 
become the most important chronic disease in first and 
third world countries and effects approximate 40% of the 
global population [24]. The effects of SCFA, phytosterol 
and phytostanols in high fibre diets and their actions on 
cholesterol lowering drugs such as statins on Aβ meta- 
bolism have not been addressed and have become im- 
portant to NAFLD [25-27] and AD treatment. The role of 
fatty acids [28-30] and phytosterols on liver nutrient 
sensing genes such as Sirtuin 1 (Sirt 1) and G coupled 
protein receptors (GPCR) needs to be further addressed 
with relevance to the treatment of appetite dysregulation, 
NAFLD and the metabolic syndrome in obesity and di- 
abetes that are chronic diseases associated with the in- 
creased risk for AD [31]. 
2. Cholesterol and AD Pathogenesis 
The main constituent of senile plaques associated with 
AD, namely Aβ [32] is a proteolytic product of a larger 
protein, the amyloid precursor protein (APP). The Aβ 
(1-40) is synthesized in the early secretory and endocytic 
cellular pathways and the Aβ (1-42) is generated mainly 
in the secretory pathway [33]. APP is cleaved by three 
proteases, classified as α, β and γ secretases and forma- 
tion of Aβ from APP is thought to occur via a two step 
process involving the β-site cleaving enzyme (BACE) 
and the putative γ-secretases [34-36]. The APP protein is  
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cleaved into βAPPs (amino acids 18-671 of APP) and Aβ 
(amino acids 672-711/713 of APP). Cholesterol has been 
shown to be directly involved in membrane APP/Aβ in- 
teractions and alterations in these interactions may be 
involved in the early stages of amyloidogenesis [37,38]. 
Detailed studies have previously shown that plasma 
high density lipoprotein (HDL) and low density lipo- 
protein (LDL) cholesterol levels in AD patients when 
compared to age matched individuals [39-41] were signi- 
ficantly correlated to cognitive decline [41]. The liver and 
membrane cholesterol homeostasis has been shown to be 
involved with HDL levels and the ATP-binding cassette 
transporter (ABCA1) plays an important role in APP 
processing and peripheral cholesterol homeostasis with 
maintenance of central nervous system and neuronal Aβ 
and cholesterol homeostasis [42-45]. Interests in peri- 
pheral cholesterol metabolism have accelerated since 
clearance and metabolism of Aβ oligomers are important 
factors involved in the progression of amyloid plaque 
development. In the brain, cholesterol levels can also be 
regulated by sterol regulatory element-binding proteins 
(SREBP) that belong to the family of transcription factors 
that regulate intracellular cholesterol and lipid metabolism 
[46]. 
The role of cholesterol in modulating the expression of 
APP and the levels of Aβ has been reported [47-50]. 
Cholesterol modulates Aβ levels and Aβ acts on lipid 
metabolism by inhibiting cholesterol synthesis by inhibi- 
tion of 3 hydroxy 3 methylglutaryl coenzyme A (HMG- 
CoA) and plays an important role in sphingomyelin me- 
tabolism to form ceramide [51]. The enzyme acyl-coen- 
zyme A: cholesterol acyltransferase 1 (ACAT) esterifies 
cholesterol and long chain fatty acids and the enzyme 
controls Aβ and cholesteryl ester generation in the intes- 
tine and liver [52-54]. In the liver, the cholesteryl esters 
have a profound effect on APP processing and inhibition 
of the ACAT1 enzyme may reduce Aβ with effects on Aβ 
plaque development [54]. Both enzymes are closely in- 
volved in LDL receptor regulation and several reviews 
have shown that LDL receptors (LDLr) are involved in 
cholesterol homeostasis, APP processing and AD patho- 
genesis [55-57]. In LDL receptor deficient mice, elevated 
LDL levels were associated with cerebral amyloidosis and 
in human, polymorphisms in the LDL receptor gene were 
associated with AD [55-56]. In the brain and liver, the 
LDL receptors play an important role in the metabolism of 
cholesterol and Aβ with the LDL receptor related protein 
1 (LRP1) closely linked to AD. LRP1 also acts on blood 
brain barrier for the transport of Aβ to the periphery from 
the brain [58,59]. LRP1 is involved in the clearance of 
apolipoprotein E (apo E), alpha 2 macroglobulin, trans- 
forming growth factor-beta, and tissue plasminogen acti- 
vator (tPA). Other members of the LDL receptor family 
such as apo ER2, LRP1B, and sorting protein related re-  
ceptor containing LDL receptor class A repeats (SORLA) 
are involved in APP and Aβ metabolism [60, 61]. The re- 
ceptor for advanced glycation end products (RAGE) may 
allow transport of Aβ from the plasma into the brain but 
LRP1 in man predominates for the major pathway for trans- 
port of Aβ from the brain into the plasma (Figure 2). 
Interests in lowering peripheral cholesterol levels to 
reduce the risk of AD have been the focus of many re- 
search studies with particular impact in the regulation of 
brain Aβ metabolism. The interests in low HDL and high 
LDL in the plasma of AD patients have increased research 
in food and nutrition to assess the role of atherosclerosis in 
obesity and diabetes. Diets and brain cholesterol homeos- 
tasis has gained central interest to AD since cholesterol 
has not been reported to cross the BBB [62-64]. The brain 
must obtain cholesterol from de novo synthesis with as- 
trocytes and oligodendrocytes mainly involved in cho- 
lesterol synthesis and neurons account for a small amount 
of the brain cholesterol [65,66]. Diets that promote neuron 
and maintain synapse are vital in the treatment of AD 
since there is a gradual loss of nerve synapses in brain 
regions in AD which is associated with disturbed choles- 
terol homeostasis [67,68]. Brain cholesterol homeostasis 
is maintained by cholesterol excretion in the form of 24S- 
hydroxysterol (24 S OHC) accomplished by the cytoch- 
rome P450 species [69] and in man the brain releases 
approx. 6 mg of 24S OHC into the periphery each day that 
is removed predominantly by the liver [70]. In AD pa- 
tients, studies have shown that cholesterol metabolism is 
disturbed with elevated 24S OHC levels possibly related 
to neuronal death and neurodegeneration [71-73]. The 
release of 24 S OHC from the brain is critical to the main- 
tenance of neurons and synapses and it cannot be excluded 
that with aging the elevated release of oxysterols from 
phytosterols in the brain may also be involved in abnormal 
neuron survival and synapse maintenance. 
Drugs such as statins are inhibitors of HMG-CoA re- 
ductase and up-regulate LDL receptor levels with reduc-  
 
 
Figure 2. Phytosterols regulate intestine, liver and brain 
cholesterol and amyloid beta metabolism. 
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tion in LDL levels [74,75]. Cholesterol lowering drugs 
have been shown to have marked effects on Aβ levels with 
statins involved in the reduction of Aβ levels [76-80]. The 
mechanisms of actions of statins on lowering the risk of 
AD may involve membrane interactions by adjusting 
cholesterol and other specific sterols sensitive to Aβ ho- 
meostasis. The role of diets and drug therapy may allow 
maintenance of membrane cholesterol levels that main- 
tain proper synaptic function and abnormal events from 
drugs such as statins in relation to injury to mitochondria 
and muscles could be avoided with specific high fibre diet 
interventions that allow long term use of drug therapy.  
3. Phytosterols and Cholesterol Homeostasis 
In large scale studies in man Western diets that contain  
high fat and high cholesterol contents have been asso- 
ciated with increased risk for AD and in experimental 
studies in rodents HFHC diets lead to increased brain Aβ 
levels and abeta plaque like deposits in the brain [81,82]. 
In studies with mediterranean diets high in fibre low in fat 
content, high in antioxidant, trace mineral and fish content 
with active lifestyles was associated with decreased risk 
for AD [81,82]. Interests in high fibre diets and their ef- 
fects on other neurodegenerative disease such as Parkin- 
son’s disease (PD) and Hungtington’s disease (HD) have 
been reported with the higher caloric intake associated 
with the increased risk for PD and HD [83-90]. Nutritional 
therapy in neurodegeneration has become important with 
effects on nutrient sensing receptors such as Sirt1 and 
GPCR in the liver and brain with particular interests in 
pharmacotherapy with GPCR targets in PD and HD [91, 
92]. GPCRs or fragments may bind second messengers 
that directly initiate or regulate transcriptional events in 
the nuclear domain [93-95] and GPCR regulation of nuc- 
lear events are possibly associated with nutritional regu- 
lation by dietary cholesterol or low calorie high fibre 
diets. Elevated cholesterol levels and oxidative stress 
induced by HFHC diets modify membrane cholesterol 
[96] with the alteration in membrane GPCR function or 
transport of GPCR to the nucleus. 
In neurodedgeneration, neuronal dysfunction that leads 
to death plays a pivotal role in neuronal loss and the hy- 
pothesis that phytosterols are involved in the regulation 
of neuronal cholesterol and Aβ metabolism has focused 
on the role of these phytonutrients that may underline the 
AD disease process. Foods that maintain brain health are 
essential for the aging communities in various countries. 
The ability to alter dietary composition of fibre, fat and 
cholesterol allows the nutritionist to increase the survival 
of neurons and to withstand programmed cell death and 
maintain cognition and brain function. In Western com- 
munities, individuals synthesize approx 1 gram of cho- 
lesterol per day and consume 400 mg from their diet. 
Phytosterol consumption and its ability to maintain 
plasma cholesterol and membrane cholesterol are impor- 
tant to the pathogenicity of neuronal Aβ with consumption 
of approx. 2 g per day associated with reduction in cho- 
lesterol absorption with effects on membrane cholesterol 
molecular mechanisms [97-99]. 
Brain cholesterol homeostasis and phytosterol intake 
are closely interlinked and diets with specific composition 
of phytosterols are possibly important in the maintenance 
of liver, brain and oxysterol metabolism [97-106]. Phy- 
tosterols such as campesterol and stigmasterol inhibit 
intestinal cholesterol absorption and beta-sitosterol and 
stigmasterol act on the liver to reduce cholesterol levels 
(Figure 2, ref [97,99,101]). In the cerebrospinal fluid, 
brassicasterol has been detected and is reported to be a 
significant biomarker for AD with indication of altered 
transport of this phytosterol to the brain [102]. In aging 
and senescence, phytosterols accumulate in the brain with 
loss of control of cholesterol and oxysterol metabolism 
and transport within the brain [105-108]. Specific phy- 
tosterols such as beta sitosterol that regulate cholesterol 
levels also control APP processing and Aβ production in 
platelets [109,110] with current interest of specific phy- 
tosterols to nutrition science and AD (Figure 2). The role 
of phytosterols in the regulation of intestine, liver and 
brain cholesterol is critical to Aβ metabolism and meta- 
bolism of cerebral oxysterols which is closely related to 
neurodegenerative diseases [111-117]. 
The interest in phytosterols in AD has accelerated 
since the incidence of liver disease, obesity and diabetes 
has increased with the incidence of AD. Interests in the 
peripheral sink Aβ hypothesis in relation to phytosterol 
metabolism and their regulation of peripheral cholesterol 
homeostasis (vice versa) have been the focus of dietary 
fibre and relevance to AD. In Western countries, nutri- 
tional therapy has targeted the therapies for liver diseases 
and NAFLD is common in these countries [118]. Phy- 
tosterols have clear effects on the liver X receptors (LXR) 
and ATP-binding cassette transporters (ABCA1) path- 
ways unravelling the mechanisms for the control of cell 
and membrane cholesterol homeostasis [119-123]. The 
LXRs are nuclear receptors that are found in the brain 
and influence a variety of genes involved in cellular cho- 
lesterol efflux and cells of the CNS [81,82]. The target 
gene for LXR is ABCA1 and activation of LXR has been 
shown to stimulate ABCA1 levels and decrease Aβ levels 
[81,82]. 
Sirt1 belongs to the HDAC family and the role of this 
anti-aging protein is linked to cholesterol and Aβ meta- 
bolism with links to obesity, diabetes and AD [2,124]. 
Sirt1 positively regulates the nuclear receptor LXR and in 
vivo reduces the expression of LXR targets such as AB-
CA1. In obesity and diabetes, Sirt 1 is switched off and the 
effects of phytosterols may be ineffective on cholesterol 
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homeostasis via LXR and ABCA1 pathways that provide 
important dietary modulation of the nuclear receptor 
control of cholesterol and Aβ homeostasis in the liver and 
brain. Sirt 1 is involved in fatty acid metabolism, appetite 
and circadian control with involvement of peroxisome 
proliferator-activated receptors (PPAR) that are affected 
by fatty acids with significance to the PPAR alpha-Sirt 1 
complex and peripheral amyloidogenesis [2]. Phytosterols 
regulate gene expression and cell cholesterol homeostasis 
and determine the LDL receptor membrane expression 
with effects on LDL concentrations in man. Phytosterols 
are closely involved in nutrigenomics with control and 
regulation of the nuclear receptor Sirt 1 actions that con-
trol cholesterol and Aβ levels (Figure 3 (ref [2,119-123, 
124]). 
Diet and cholesterol therapy using drugs has been the 
central focus for the treatment of AD. Caloric restriction 
and exercise do not only affect cholesterol metabolism 
but also phytosterol metabolism with prevention of the 
accumulation of oxysterols and phytosterols in the liver 
and brain membranes [115,116]. A major focus on the 
use of diet, cholesterol lowering drugs and lifestyles is to 
increase neuron number and decrease the size of plaques 
in the brain with aging. The membrane interactions of Aβ 
require cholesterol for clearance and metabolism with the 
increase in the membrane cholesterol involved in the 
regulation of Aβ assemblies [125-127]. The role of ca- 
loric restriction in activation of HDAC genes which con- 
trol membrane cholesterol and the role of phytosterols 
and phytostanols (Figure 4 [99-102] have become of 
central interest since membrane interactions with choles- 
terol and Aβ may be required for the clearance and me- 
tabolism of Aβ. Increasing membrane phytosterol con- 
tents may control unstable protein/lipid complexes with 
the composition of phytosterols essential for neuron 
number and survival. Membrane phospholipids have 
been shown to be important for insertion of Aβ and the 
role of phytosterols (beta-sitosterol) in the determination 
of cholesterol/phospholipid stability has been reported 
[128-130]. Furthermore, the displacement of cholesterol 
by phytosterols or phytostanols may have implications 
for Aβ insertion and aggregation [131-133]. 
In various species, phytosterols are absorbed with dif- 
ferent rates with low phytosterol absorption rates in rab- 
bits and high phytosterol absorption rates in man. The 
role of diet and membrane phytosterols in cell mem- 
branes has attracted interest since the important role of 
cholesterol in ion channel regulation has been reported. 
Membrane lipids are an important part of the structure of 
neurons and conduct electrical impulses in association 
with membrane proteins [134-136]. Lipids are an integral 
component of bilayer membranes and maintain ion 
channels that are involved in intercellular communication 
[134,135]. Lipids within membranes are involved in  
 
Figure 3. Fatty acids and phytosterols control PPAR-HDAC 
by caloric regulation of nuclear receptors with effects on 
cell cholesterol metabolism via liver X receptors and ATP 
binding cassette transporters. 
 
maintaining membrane potentials by regulating the 
movement of ions across neuronal membranes, maintain 
synaptic function and produce lipid messengers for signal 
transduction [137]. The association of phospholipids, 
glycosphingolipids such as ceramide or gangliosides, 
glycerophospholipids (plasmalogen) and sterols makes 
up the membrane bilayers in neurons and packing of 
cholesterol within membranes may have marked effects 
on membrane protein structure and function and regula- 
tion of ion pumps [138]. Lipid rafts containing sphingo- 
myelin and cholesterol form micro-domains for the re- 
cruitment of lipid modified proteins and ion channels 
[134]. Cholesterol has been shown to be involved in the 
regulation of ion channels and Aβ has been shown to 
closely regulate various ion channels [139-142]. In par- 
ticular, Aβ oligomer formation is cytotoxic and leads to 
neuronal death with alterations in membrane ion channel 
activity and synaptic plasticity [143,144]. The role of 
specific phytosterols in the brain and their effects on the 
regulation of cholesterol and ion channels are poorly 
understood and diets that contain specific phytosterols 
and their relationship to Aβ and ion channels may have 
important implications for aging and AD. 
4. Synergistic Effects of Phytosterol and  
Fatty Acids 
Phytosterols and SCFA are natural food components with 
potential health benefits. Both compounds are mainly 
derived from high fibre diet and have properties such as 
anti-cancer [145] anti-atherosclerotic, anti-inflammatory 
[146-149] and anti-oxidant [150,151]. Phytosterol reduce 
cholesterol levels and an increase in the level of butyric 
acid, propionic and acetate in the blood is associated with 
a significant reduction in plasma cholesterol levels [152, 
153]. Low molecular size, short carbon chain length and 
a high water solubility of SCFA have facilitated its rapid 
absorption in the portal vein and metabolism [154]. 
Higher metabolism rate of butyric acid has reduced its  
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Figure 4. Phytosterols and phytostanols found in high fibre diets. 
 
clinical potential. Thus it is reasonable to suggest that 
combination of phytosterol and SCFA may further reduce 
cholesterol and increase its efficacy as an anti cancer, 
anti inflammatory and anti-oxidant agent. Esterification 
of phytosterol with short chain fatty acids may improve 
its integration into a variety of foods without disturbing 
the efficiency of phytosterol as with omega 3 fatty acids 
and phytosterol.  
Phytosterol esters with fish oil have been found to 
lower the plasma cholesterol levels than conventional 
phytosterol esters [155]. Furthermore, this synergistic sup- 
plement has a more hypotriglyceridemic effect than the 
conventional fish oil [155]. Esterification of phytosterol 
with oleic acid and esterification of beta sitosterol with 
conjugated linoleic acid have been previously reported 
[156]. Esterification of phytosterol with SCFA or espe-
cially with butyric acids has been poorly reported. Recent 
studies have shown formation of phytosterol esters via 
direct esterification with butyric acid and via trans esteri-
fication with tributyrin and ethyl butyrate [157]. Animal 
studies will be helpful to understand this combination 
while human studies are required to identify its long term 
effects. On the other hand, aliphatic and steroid esters of 
gamma-amino [U-14C] butyric acid (GABA) which is a 
synthesized compound have proved to have a high pene- 
tration capacity across the blood brain barrier [158]. 
The combination of SCFA and phytosterols on choles- 
terol homeostasis indicate that high fibre diets are regu- 
lators of amyloidosis and may prove effective as AD 
therapy. Studies have shown that SCFA are formed as a 
result of fibre fermentation could be affected by the con- 
sumption of phytosterol. Consumption of margarine en- 
riched with phytosterol esters did not show any effect on 
the micro flora profile or to their metabolic activities or 
SCFA content [159]. SCFA have effects on appetite con-
trol and are considered to be important to HDAC inhibi-
tion (Figure 3) which is currently an important therapy 
for AD. SCFA exhibit marked effects on free fatty acid 
metabolism on binding to G coupled receptors that are 
involved in appetite control and play an important role in 
obesity and AD [160-162]. SCFA have been shown to 
have marked effects on insulin sensitivity and lipid me- 
tabolism and are associated to the field of insulin resis- 
tance syndrome and AD. Apart from synergistic effects 
of phytosterol and SCFA as AD therapy in particular bu- 
tyric acid may have independent effects on AD. Interest 
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in the effects of butyric acid on liver has increased since 
NAFLD has become common in Western countries with 
close association with obesity and diabetes that are high 
risk factors for AD. Sodium butyrate contains anti-in- 
flammatory and cancer chemo-preventive properties in 
colon [163-165]. Acetate, propionate and butyrate have 
the ability to transport through the blood brain barrier 
and could be utilized as the energy source by short-chain 
L-3-hydroxyacyl-CoA dehydrogenase [166]. This en-
zyme is highly important to Aβ and known as endop- 
lasmic reticulum amyloid beta-peptide-binding protein 
and as a multifunctional protein has the capacity to oxi- 
dise oxidize 17β-estradiol [166]. The anti-cancer and 
anti-proliferative features of butyrate are not important to 
energy metabolism but may be vital to the modulation of 
gene expression [167] via the inhibition of histone dea- 
cetylases [165] and NF-κB signaling [168]. Studies have 
shown that butyrate could effect gene expression in mi- 
croglial cells, as in colonocytes [167]. 
Butyrate could induce the adaptive responses in NF- 
κB signaling and has a capacity to regulate the respon- 
siveness of microglial cells to lipopolysaccahrides (LPS). 
Research studies on colonocytes [164], intestinal epi- 
thelial cells [169] and murine macrophages [168] has 
demonstrated that butyrate could down-regulate NF-κB 
signalling induced by cytokines or LPS. Yin et al. (2001) 
have shown that butyrate could inhibit proteasome activ- 
ity and has the ability to up-regulate the level of inhibi-
tory IκB proteins and thus prevents the cytosolic NF-κB 
activation. In other studies, butyrate has been shown to 
[170] down-regulate the expression of Toll-like receptor 
4 (TLR4) that transmits LPS signals to activate NF-κB 
system and suggests that butyrate could suppress NF-κB 
activation. It may be interesting to understand the effect 
of sodium butyrate on the inhibition of NF-κB signaling 
in microglial cells. Discharge of proinflammatory and/or 
cytotoxic factors, including tumor necrosis factor-alpha 
(TNF-α), interleukin 1-beta (IL-1β), interleukin-6 (IL-6), 
interleukin-12 (IL-12), andnitric oxide (NO) could cause 
gradual damage in neurodegenerative diseases such as 
stroke, trauma, AD, multiple sclerosis, and human im- 
munodeficiency virus (HIV)-associated dementia. 
Dietary fibre also contains other fatty acids such as 
medium chain fatty acids and long chain fatty acids and 
also affects nuclear receptors with particular relevance to 
the PPARγ involved in an increase in insulin sensitivity 
and diabetes. LCFA activates nuclear receptor PPAR α 
and gene transcription with control of lipid and glucose 
homeostasis. Diets rich in fibre lead to synergistic effects 
of phytosterols and SCFA, MCFA and LCFA on nuclear 
receptor activity (PPAR-Sirt1) expression and activation 
that allow control of glucose and cholesterol homeostasis 
involved in prevention of obesity and diabetes being the 
risk factors for AD. 
5. Conclusion 
Phytosterols and phytostanols and their esters are found 
in oils, fats, nuts, seeds, cereal, vegetables and fruits and 
their effects on reducing cholesterol absorption and cho- 
lesterol lowering therapies have been reported. High le- 
vels of SCFA have been found in barley, oats, brown rice, 
bran, green beans, legumes, leafy greens, apples, kiwi 
and oranges. Medium chain such as lauric acid and long 
chain fatty acids has been found in coconut oil. Interest 
in high fibre diets as anti-Alzheimer’s or anti-diabetic 
and their effects on drug therapy such as statins have at- 
tracted considerable interest although plasma cholesterol 
is clearly reduced in the drug therapy and effects on phy- 
tosterol interactions on membranes need to be further 
addressed in relation to promotion of Aβ binding, clear- 
ance and metabolism. The peripheral clearance of Aβ and 
its relationship to high fibre diets is of particular interest 
to therapy in AD because high fibre diets are particularly 
effective in NAFLD treatment and assist in the rapid 
brain transport of Aβ to the liver. The role of SCFA and 
phytosterols on nutrient sensing genes such as Sirt1 and 
G coupled protein receptors indicates the therapeutic role 
of high fibre diets on appetite regulation and the meta- 
bolic syndrome in chronic diseases such as obesity and 
diabetes and their increased risk for AD, PD and HD. 
Dietary fibre intake may improve the actions of statins by 
activation of nutrient sensing genes with synergistic ef- 
fects of cholesterol lowering drugs and diet on improving 
peripheral Aβ metabolism in AD individuals. 
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